subject: Prot.ob Stock Report Brought To You By Pennytobuck.com [print this page] Proteonomix, IncProteonomix, Inc. (PROT.OB)
As a research and development company focused on stem cell therapies for diabetes and cardiac injury, PROT has innovation at heart.
PROT is planning to lead the research community into the future by introducing a new platform for growing contaminant-fee human stem cells that will serve as a catalyst for bringing feasible therapies to market.
With umbilical cord blood stem cells already being recognized as a viable treatment for more than 80 diseases and that number continuing to grow in the future, PROT is also preparing to establish a cord blood bank that employs proprietary technology that will lead to a significant increase in the donor-recipient match rate. PROT will also be launching a genetic diversity program to increase the currently under-represented minority groups in the pool of available cord blood stem cell units.
PROT is working with top scientists and institutions around the world.
Stem Cell treatments for a variety of diseases are just over the horizon some 80 diseases have already been identified that Stem Cells could help
Mr. Michael Cohen, Chairman and CEO of PROT, stated, We have no doubt that stem cell therapies will be a major factor in combating a variety of medical conditions but it is essential that it be undertaken only after the clinical results determine that such a course of action is efficacious. Too much hype about cures for all types of diseases is diminishing the potential value of stem cells and could unduly delay future progress in stem cell treatments and research. Medical tourism is not a dirty word, if established in an ethical and professional manner.
Cohen added, At Proteonomix we have adopted a rigorous and cautious approach that will ensure that patients that are ultimately treated by us have confidence that the procedures will be safe, relatively low cost and offering the best chance for alleviating their specific medical condition. Our research progress has been dramatic and the procedures and intellectual property portfolio, made up of a significant number of pending patents, have resulted in Proteonomix emerging as a leader in the development of stem cell medical treatments.
This is a biotech company that may be one of the leaders in this field; you may want to add them to your radar screen
About Proteonomix, Inc. (PROT.OB)
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc., a wholly owned subsidiary of Proteonomix, has recently opened its retail web site, Proteoderm.com, and began accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development of therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
